

SYNOPSIS OF RESEARCH REPORT [REDACTED]

PROTOCOL BO18040

COMPANY: F.Hoffmann-La Roche NAME OF FINISHED PRODUCT: Bondronat® NAME OF ACTIVE SUBSTANCE(S): ibandronic acid	(FOR NATIONAL AUTHORITY USE ONLY)						
TITLE OF THE STUDY / REPORT No. / DATE OF REPORT	A randomized, two arm, placebo controlled study to compare the efficacy of intravenous loading doses followed by maintenance treatment with intravenous ibandronic acid versus zoledronic acid in patients with skeletal metastases experiencing moderate to severe pain / Protocol BO18040 / Abbreviated Study Report [REDACTED] October 2007.						
INVESTIGATORS / CENTERS AND COUNTRIES	Multicenter Trial / 44 centers in 15 countries						
PUBLICATION (REFERENCE)	none						
PERIOD OF TRIAL	01 Aug 2005 – 29 Jan 2007	CLINICAL PHASE	III				
OBJECTIVES	<p><u>Primary Objective:</u> To compare the difference in pain responses between treatment with ibandronic acid vs. zoledronic acid in patients with malignancy and painful metastatic bone disease.</p> <p><u>Secondary Objectives:</u></p> <ul style="list-style-type: none"> • Pain response determined by the “AVERAGE PAIN” scale of the BPI. • Duration of pain response based on the WORST PAIN and AVERAGE PAIN scales of the BPI. • Time to pain response based on the WORST PAIN and AVERAGE PAIN scales of the BPI • Interference scales of the BPI • Analgesic consumption, expressed as Opioid equivalents • Opioid side-effects • WHO Performance Score • Quality of life measured by the EORTC QLQ-C30 scale • Quality of life measured by the FACT-BP scale • Patient Global Assessment <p>Due to the insufficient number of subjects recruited into the study as a result of the premature termination of enrollment, the primary objective could not be achieved. The primary objective of the current report was to present a full analysis of the safety data from this trial.</p>						
STUDY DESIGN	Multicenter, randomized, active-controlled, double-blind, parallel group trial						
NUMBER OF SUBJECTS	<u>BO18040</u> : Enrolled n = 164 <u>No. Evaluated</u> <table style="width: 100%; border: none;"> <tr> <td style="width: 60%;"></td> <td style="text-align: center;"><u>Safety</u></td> </tr> <tr> <td>Ibandronic acid group</td> <td style="text-align: center;">84</td> </tr> </table>				<u>Safety</u>	Ibandronic acid group	84
	<u>Safety</u>						
Ibandronic acid group	84						

SYNOPSIS OF RESEARCH REPORT

PROTOCOL BO18040

COMPANY: F.Hoffmann-La Roche	(FOR NATIONAL AUTHORITY USE ONLY)
NAME OF FINISHED PRODUCT: Bondronat®	
NAME OF ACTIVE SUBSTANCE(S): ibandronic acid	

METHODOLOGY:

Ibandronic acid was administered as a loading dose of 6 mg intravenously daily for 3 days, followed by treatment with 6 mg IV every 3-4 weeks. Zoledronic acid was administered in a dose of 4 mg intravenously every 3 – 4 weeks, depending on the underlying chemotherapy regimens patients were receiving. Patients received intravenous zoledronic acid placebo on Days 2 and 3 of the first zoledronic acid treatment only. Treatment was continued for 24 weeks. Patients recorded their pain on the WORST PAIN and the AVERAGE PAIN scales of the BPI, as well as daily analgesic use, on a nightly basis. Patients recorded the degree to which their pain interfered with normal functioning and any opioid side-effects weekly. WHO Performance Status, patient quality of life based on the EORTC QLQ-C30 instrument and quality of life based on the FACT-BP, an instrument specifically designed to measure quality of life in patients with bone pain were recorded at Day 8 and Weeks 6, 12, 18 and 24 of the trial. Patients had skeletal surveys performed at baseline and at Weeks 12 and 24 as part of the monitoring of SREs. Adverse events and laboratory safety parameters were assessed throughout.

SAFETY RESULTS:

Overall, 85% of patients in the ibandronic acid treatment group and 83% of patients in the zoledronic acid treatment group reported at least one adverse event during the trials. Gastrointestinal Disorders were the most frequently reported adverse events, the most common being nausea which was reported by 20% of patients in the ibandronic acid group and 19% of patients in the zoledronic acid treatment group. In general, the types of adverse event reported during the trial were similar in the two treatment groups.

The incidence of grade III adverse events during the study was similar in the ibandronic acid and zoledronic acid treatment groups (37% vs 44%, respectively). Anemia (4 ibandronic acid patients, 7 zoledronic acid patients) was the most frequently reported grade III event in either treatment group. Eleven ibandronic acid patients and 12 zoledronic acid patients reported at least one grade IV adverse event during the studies. No grade IV adverse events were considered related to ibandronic acid treatment or zoledronic acid treatment.

A total of 15 patients (18%) in the ibandronic acid group and 17 patients (21%) in the zoledronic acid group died. The most common reason for death was for disease progression of the underlying cancer. None of the deaths was considered related to trial treatment.

Serious adverse events were reported by 33% (28/84) of patients in the ibandronic acid group and 39% (31/80) of patients in the zoledronic acid group. The most common individual SAE was anemia reported in 2 ibandronic acid patients and 5 zoledronic acid patients. During the studies, 5% of patients in ibandronic acid group and 15% of patients in the zoledronic acid treatment group discontinued treatment because of one or more adverse events. Adverse events of special interest in this patient population receiving bisphosphonate therapy were skeletal related events and renal events. There were no differences between the treatment groups with respect to the frequency of skeletal related adverse events and the time to first skeletal related event was similar between the two groups. The incidence of renal events in both studies was low and no marked deterioration in renal function was seen in either treatment group during the treatment period. Among the small percentage of subjects for whom a deterioration in renal function was observed, a slight difference between the treatment groups, in favor of the ibandronic acid treatment group, was seen with respect to the time to renal deterioration, however this difference was not considered to be of clinical relevance.

The mean changes from baseline in hematology, blood chemistry or urinalysis parameters were similar in the two treatment groups and there were no clinically relevant differences between the treatment groups

SYNOPSIS OF RESEARCH REPORT [REDACTED]

PROTOCOL BO18040

COMPANY: F.Hoffmann-La Roche	(FOR NATIONAL AUTHORITY USE ONLY)
NAME OF FINISHED PRODUCT: Bondronat®	
NAME OF ACTIVE SUBSTANCE(S): ibandronic acid	

with respect to grade 3 or grade 4 laboratory test parameter values reported during the study. Changes from baseline values in vital signs parameters were also comparable in the ibandronic acid and zoledronic acid treatment groups.

CONCLUSIONS:

Within the limitations of the early termination of study BO18040, the results demonstrate that a regimen of 3 consecutive IV doses of ibandronic acid over 3 days followed by maintenance therapy with IV ibandronic acid 6 mg every 3-4 weeks has a comparable safety profile to that of zoledronic acid 4 mg every 3-4 weeks in patients with bone pain due to metastatic bone disease. No new or unexpected safety findings were identified which would alter the known safety profile of ibandronic acid in cancer patients with bone metastases.